Specipig has expanded its facilities, in the Barcelona area, to a total surface area of 2,400 square metres in order to boost its capacity as a benchmark preclinical Contract Research Organization (CRO) in the biomedical sector.
The company currently has three fully equipped operating sites, one analytical laboratory, research facilities and offices, and a team of over 20 qualified professionals.
“We continue to invest in facilities, technology and talent to provide high-quality service. We aim to help optimize the whole preclinical phase for new drugs, advanced therapies, devices and medical technology outsourced by the pharmaceutical, biotechnology and medical technology industry, hospitals and research centres across the globe,” explains Jaume Amat, CEO at Specipig.
Specipig’s services encompass everything from the start of the preclinical phase through regulatory approval (proof of concept, efficacy and safety studies, regulatory toxicology studies, biocompatibility, testing medical devices, validation of medical devices etc.) in the following therapeutic areas: cardiovascular, abdominal, respiratory, ophthalmology, dermatology, urology, neurology, dental and neonatal.
Specipig has Good Laboratory Practices (GLP) certification and meets the guidelines issued by the European Medicines Agency (EMA), the US Food and Drug Agency (FDA), ISO 10993 and other relevant healthcare authorities. In the coming months, the company expects to receive ISO 13485 certification for medical devices.